5月21日盘中，三生制药股价继续走高，截至9:35，该股大涨5.32%，延续了昨日的强劲涨势。
消息面上，三生制药昨日（5月20日）宣布与辉瑞达成重磅合作协议，将向辉瑞独家授予其自主研发的PD-1/VEGF双特异性抗体SSGJ-707在全球（不包括中国内地）的开发、生产、商业化权利。根据协议，三生制药将获得12.5亿美元首付款，以及最高可达48亿美元的里程碑付款，此次交易的潜在总金额高达60.5亿美元。
这一重磅交易引发了资本市场的强烈反应。昨日三生制药港股股价飙升超30%，今日开盘后继续走高。分析人士认为，这笔交易不仅为三生制药带来了可观的现金流入，也彰显了其创新药研发实力得到国际巨头的认可，有望进一步提升公司在全球生物医药市场的地位。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.